The existence and functioning of a comprehensive drug regulatory system supported by legislation is a prerequisite for an overall quality assurance system. The first duty of a national regulatory authority is to register pharmaceutical products, thus defining the pharmaceutical market in the country. Iceland, Liechtenstein, and Norway, not joined the EU, have partly committed to the EU's economy and regulations and are a part of the single market through the EEA. Switzerland has similar ties through bilateral treaties. Andorra, Monaco, San Marino, and VaticanCity include the similar co-operation. Countries: Croatia, Republic of Macedonia, Turkey, as Serbia, Bosnia and Herzegovina, Serbian Republic, Montenegro, and Albania, that are officially recognised as potential candidates, as Kosovo and other responding countries (Armenia, Azerbian, Belarus, Georgia, Moldova, Russia, Ukraine), reported about new medicines laws in accordance with the EU legislation, developing EU-harmonization and modernizing their regulatory authority by establishing drug agencies according to models in EU.
展开▼
